Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Income towards Parent Company (2021 - 2025)

Lyra Therapeutics has reported Income towards Parent Company over the past 5 years, most recently at -$7.0 million for Q4 2025.

  • Quarterly results put Income towards Parent Company at -$7.0 million for Q4 2025, up 36.69% from a year ago — trailing twelve months through Dec 2025 was -$28.9 million (up 69.05% YoY), and the annual figure for FY2025 was -$28.9 million, up 69.05%.
  • Income towards Parent Company for Q4 2025 was -$7.0 million at Lyra Therapeutics, down from -$6.0 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for LYRA hit a ceiling of -$6.0 million in Q3 2025 and a floor of -$48.1 million in Q2 2024.
  • Median Income towards Parent Company over the past 5 years was -$12.8 million (2021), compared with a mean of -$14.2 million.
  • Biggest five-year swings in Income towards Parent Company: crashed 208.18% in 2024 and later skyrocketed 84.55% in 2025.
  • Lyra Therapeutics' Income towards Parent Company stood at -$13.6 million in 2021, then decreased by 4.44% to -$14.2 million in 2022, then dropped by 6.57% to -$15.2 million in 2023, then increased by 27.56% to -$11.0 million in 2024, then skyrocketed by 36.69% to -$7.0 million in 2025.
  • The last three reported values for Income towards Parent Company were -$7.0 million (Q4 2025), -$6.0 million (Q3 2025), and -$7.4 million (Q2 2025) per Business Quant data.